M&A / Deals LEO Pharma to acquire gene therapy company Replay Pharmaceutical Business ReviewThe acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector.Gene Therapy PlatformRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. Gene Therapy Platform Read full story Post navigation Previous: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant openingNext: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026